Heidi Cuthbert

Costamare Bulkers (NYSE:CMDB) reported first-quarter net income of $9.9 million, or $0.41 per share.

Altimmune (NASDAQ:ALT), a clinical-stage biopharmaceutical company developing treatments for metabolic and liver diseases, reported its first-quarter 2026 financial results and provided a business update.

Similarweb (NYSE:SMWB) reported a significant improvement in its financial health for the first quarter of 2026, swinging to a non-GAAP operating profit as the company scales its footprint among high-value enterprise clients.

Voyager Therapeutics (NASDAQ:VYGR) achieved a critical regulatory milestone this week, presenting positive three-month toxicology data for its lead Alzheimer’s disease candidate, VY1706.

Regis Corporation (NASDAQ:RGS) demonstrated improved operational efficiency in its third fiscal quarter, reporting a significant rise in net income and earnings per share despite a contraction in its top-line revenue.

Takeda Pharmaceutical (NYSE:TAK) reported fiscal year 2025 results that met its revised management guidance, as the company utilized aggressive operational savings to buffer the impact of generic competition for its top-selling ADHD medication, Vyvanse.

Innate Pharma (NASDAQ:IPHA), a clinical-stage biotechnology company specializing in immuno-oncology, announced its business update and consolidated financial results for the quarter ended March 31, 2026.

Arafura Rare Earths (ASX:ARU) has formalised a strategic partnership by signing a binding offtake term sheet with Traxys North America.

Treasurer Jim Chalmers detailed a $77 billion budget boost driven by NDIS savings and housing tax reforms to improve affordability.

Alphabet's (NASDAQ:GOOGL) Google is in discussions with Elon Musk’s SpaceX for a rocket launch agreement to deploy a network of orbital data centers, according to people familiar with the matter.